Application No.: 10/575,096

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the

application:

LISTING OF CLAIMS:

(currently amended): A process for producing an antibody composition using a

cell, which comprises using a cell into which a double-stranded RNA comprising an RNA

selected from the following (a) or (b) and its complementary RNA is introduced:

(a) an RNA comprising the nucleotide sequence represented by any one of SEO ID

NOs:9 to 3011:

(b) an RNA consisting of a nucleotide sequence in which one or several nucleotide(s)

is/are deleted, substituted, inserted and/or added in having 80% or more homology to the

nucleotide sequence represented by any one of SEQ ID NOs:9 to 3011 and having activity of

suppressing the function of an enzyme relating to the modification of a sugar chain in which 1-

position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-

bond in a complex type N-glycoside-linked sugar chain.

2. (original): The process according to claim 1, wherein the enzyme relating to the

modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-

acetylglucosamine in the reducing end through $\alpha\text{-bond}$ in the complex type N-glycoside-linked

sugar chain is $\alpha 1,6$ -fucosyltransferase.

(currently amended): The process according to claim 2, wherein the α1,6-

fucosyltransferase is a protein encoded by a DNA selected from the group consisting of the

following (a) to and (hb):

(a) a DNA comprising the nucleotide sequence represented by of SEQ ID NO:1; and

2

Application No.: 10/575,096

(b) a DNA comprising the nucleotide sequence represented by SEQ ID NO:2;

- (c) a DNA comprising the nucleotide sequence represented by SEQ ID NO:3;
- (d) a DNA comprising the nucleotide sequence represented by SEQ ID NO:4;
- (e) a DNA which hybridizes with a DNA consisting of to the nucleotide sequence that is entirely complementary to represented by SEQ ID NO:1 under stringent conditions and encodes a protein having a1,6-fucosyltransferase activity;
- (f)— a DNA which hybridizes with a DNA consisting of the nucleotide sequence represented by SEQ ID NO:2 under stringent conditions and encodes a protein having α1,6fucosyltransferase activity;
- (g) a DNA which hybridizes with a DNA consisting of the nucleotide sequence represented by SEQ ID NO:3 under stringent conditions and encodes a protein having α1,6fucosyltransferase activity;
- (h) a DNA which hybridizes with a DNA consisting of the nucleotide sequence represented by SEQ ID NO:4 under stringent conditions and encodes a protein having α1,6fucosyltransferase activity.
- 4. (currently amended): The process according to claim 2, wherein the $\alpha 1$,6-fucosyltransferase is a protein selected from the group consisting of the following (a) to and ($\frac{1}{2}$ b):
- (a) a protein comprising the amino acid sequence represented byof SEQ ID NO:5; and
 - (b) a protein comprising the amino acid sequence represented by SEQ ID NO:6;
 - (c) a protein comprising the amino acid sequence represented by SEQ ID NO:7;
 - (d) a protein comprising the amino acid sequence represented by SEQ ID NO:8;

Application No.: 10/575,096

(e) a protein consisting of an amino acid sequence in which one or more amino acid(s) is/are deleted, substituted, inserted and/or added in the amino acid sequence represented by SEO ID NO:5 and having at l.6 fucesyltransferase activity:

(f) a protein consisting of an amino acid sequence in which one or more amino acid(s) is/are deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ 1D NO:6 and having at 1,6 fueosyltransferase activity;

(g)—a protein consisting of an amino acid sequence in which one or more amino acid(s) is/are deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ 1D NO:7 and having at 1,6 fucosyltransferase activity;

(h) a protein consisting of an amino acid sequence in which one or more amino acid(s) is/are deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO:8 and having al.6 fucosyltransferase activity;

(i)—a protein consisting of an amino acid sequence which has 80% or more homology to the amino acid sequence represented byof SEQ ID NO:5 and having α1,6-fucosyltransferase activity;

(j) a protein consisting of an amino acid sequence which has 80% or more homology to the amino acid sequence represented by SEQ ID NO:6 and having a1,6-fucosyltransferase activity;

(k)—a protein consisting of an amino acid sequence which has 80% or more homology to the amino acid sequence represented by SEQ ID NO:7 and having α 1,6-fucosyltransferase activity:

Application No.: 10/575,096

(l) a protein consisting of an amino acid sequence which has 80% or more homology

to the amino acid sequence represented by SEQ ID NO:8 and having α1,6-fucosyltransferase

activity.

5. (previously presented): The process according to claim 1, wherein the cell into

which the RNA having activity of suppressing the function of an enzyme relating to the

modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-

acetylglucosamine in the reducing end through $\alpha\text{-bond}$ in a complex type N-glycoside-linked

sugar chain is introduced is a cell which is resistant to a lectin which recognizes a sugar chain

structure in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the

reducing end through α-bond in an N-glycoside-linked sugar chain.

6. (currently amended): The process according to claim 5, wherein the cell is

resistant to at least one lectin selected from the group consisting of the following (a) to (d):

(a) a Lens culinaris lectin;

(b) a Pisum sativum lectin;

(c) a Vicia faba lectin;

(d) an Alcuria aurantia lectin.

7. (currently amended): The process according to claim 1, wherein the cell is

selected from the group consisting of a yeast cell, an animal cell, an insect cell and a plant cell.

8. (currently amended): The process according to claim 1, wherein the cell is a

cell selected from the group consisting of the following (a) to (i):

(a) a CHO cell derived from Chinese hamster ovary tissue:

(b) a rat myeloma cell line YB2/3HL.P2.G11.16Ag.20 cell;

(c) a mouse myeloma cell line NS0 cell;

5

Application No.: 10/575,096

(d) a mouse myeloma cell line SP2/0-Ag14 cell;

(e) a BHK cell derived from Syrian hamster kidney tissue;

an antibody-producing hybridoma cell;

(g) — a human leukemia cell line Namalwa cell;

(h) an embryonic stem cell;

(i) a fertilized egg cell.

 (previously presented): The process according to claim 1, wherein the cell is a transformant into which a gene encoding an antibody molecule is introduced.

 (original): The process according to claim 9, wherein the antibody molecule is selected from the group consisting of the following (a) to (d):

(a) a human antibody;

(b) a humanized antibody;

(c) an antibody fragment comprising the Fc region of (a) or (b);

(d) a fusion protein comprising the Fc region of (a) or (b).

 (previously presented): The process according to claim 9, wherein the antibody molecule belongs to an IgG class.

12. (currently amended): The process according to claim 1, wherein the antibody composition is an antibody composition having higher antibody-dependent cell-mediated cytotoxic activity than an antibody composition produced by a parent cell into which a double-stranded RNA comprising an RNA selected from the following (a) or (b) and its complementary RNA is not introduced:

 (a) an RNA comprising the nucleotide sequence represented by any one of SEQ ID NOs:9-to-3011;

Application No.: 10/575,096

(b) an RNA consisting of a nucleotide sequence in which one or several nucleotide(s) is/are deleted, substituted, inserted and/or added inhaving 80% or more homology to the nucleotide sequence represented by any one of SEQ ID NOs:9 to 3011 and having activity of suppressing the function of an enzyme relating to the modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked sugar chain.

- 13. (original): The process according to claim 12, wherein the antibody composition having higher antibody-dependent cell-mediated cytotoxic activity is an antibody composition which comprises antibody molecules having complex type N-glycoside-linked sugar chains in the Fc region, and in which a ratio of sugar chains in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains among the complex type N-glycoside-linked sugar chains is higher than that of an antibody composition produced by the parent cell.
- 14. (original): The process according to claim 13, wherein the complex type N-glycoside-linked sugar chains are sugar chains in which 1-position of fucose is not bound to 6-position of N-acctylglucosamine in the reducing end through α-bond in the sugar chains.
- 15. (previously presented): The process according to claim 12, wherein the antibody composition having higher antibody-dependent cell-mediated cytotoxic activity is an antibody composition which comprises antibody molecules having complex type N-glycoside-linked sugar chains in the Fc region, and in which the ratio of sugar chains in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains among the complex type N-glycoside-linked sugar chains is 20% or more.
- (previously presented): The process according to claim 1, wherein the antibody composition having higher antibody-dependent cell-mediated cytotoxic activity is an antibody

Application No.: 10/575,096

composition which comprises antibody molecules having complex type N-glycoside-linked sugar chains in the Fc region, and in which the complex type N-glycoside-linked sugar chains are sugar chains in which fucose is not bound to N-acctylglucosamine in the reducing end.

- 17. (withdrawn): A cell into which an RNA capable of suppressing the function of an enzyme relating to the modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked sugar chain is introduced, and which is used in the process according to claim 1.
- 18. (withdrawn): The cell according to claim 17, wherein the enzyme relating to the modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acctylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked sugar chain is α1,6-fucosyltransferase.
- 19. (withdrawn): A cell in which an RNA selected from RNAs of the group consisting of the nucleotide sequences represented by any one of SEQ ID NOs:9 to 30 is introduced or expressed.
- 20. (withdrawn): A double-stranded RNA consisting of an RNA selected from the following (a) or (b) and its complementary RNA:
- (a) an RNA comprising the nucleotide sequence represented by any one of SEQ ID NOs:9 to 30;
- (b) an RNA consisting of a nucleotide sequence in which one or several nucleotide(s) is/are deleted, substituted, inserted and/or added in the nucleotide sequence represented by any one of SEQ ID NOs:9 to 30 and having activity of suppressing the function of an enzyme relating to the modification of a sugar chain in which 1-position of fucose is bound to 6-position

Application No.: 10/575,096

of N-acetylglucosamine in the reducing end through α -bond in a complex type N-glycoside-linked sugar chain.

 (withdrawn): A DNA corresponding to the RNA described in claim 20 and a complementary DNA to the DNA.

- 22. (withdrawn): A recombinant DNA which is obtainable by introducing a DNA corresponding to the RNA described in claim 20 and a complementary DNA to the DNA into a vector.
- 23. (withdrawn): The recombinant DNA according to claim 22, which expresses the double-stranded RNA consisting of an RNA selected from the following (a) or (b) and its complementary RNA:
- (a) an RNA comprising the nucleotide sequence represented by any one of SEQ ID NOs:9 to 30;
- (b) an RNA consisting of a nucleotide sequence in which one or several nucleotide(s) is/are deleted, substituted, inserted and/or added in the nucleotide sequence represented by any one of SEQ ID NOs:9 to 30 and having activity of suppressing the function of an enzyme relating to the modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α -bond in a complex type N-glycoside-linked sugar chain.
- (withdrawn): A transformant which is obtainable by introducing the recombinant DNA according to claim 22 into a cell.
- 25. (withdrawn): A method for constructing a cell which is resistant to a lectin which recognizes a sugar chain structure in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked

Application No.: 10/575,096

sugar chain, which comprises introducing or expressing the double-stranded RNA described in claim 20 in a cell.

26. (withdrawn): The method according to claim 25, wherein the cell which is

resistant to a lectin which recognizes a sugar chain structure in which 1-position of fucose is

bound to 6-position of N-acetylglucosamine in the reducing end through $\alpha\text{-bond}$ in a complex

type N-glycoside-linked sugar chain is resistant to at least one lectin selected from the group

consisting of the following (a) to (d):

(a) a Lens culinaris lectin;

(b) a Pisum sativum lectin;

(c) a Vicia faba lectin;

(d) an Aleuria aurantia lectin.

27. (withdrawn): A method for suppressing the function of an enzyme relating to

the modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-

acetylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked

sugar chain, which comprises using an RNA selected from RNAs of the group consisting of the

nucleotide sequences of any one of SEQ ID NOs:9 to 30.

28. (withdrawn): The method according to claim 27, wherein the enzyme relating to

the modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-

acetylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked

sugar chain is α1,6-fucosyltransferase.

10